Skip to main content
Premium Trial:

Request an Annual Quote

Tm Posts Higher Q1 Losses Despite a 170-Percent Jump in Revenues

NEW YORK, May 15 (GenomeWeb News) - Tm Bioscience reported today higher losses in the first quarter despite a 170-percent jump in revenues.

 

Revenues in the quarter climbed to $2.9 million from $1.1 million a year earlier, reflecting a 140-percent surge in product sales. The company attributed the sales growth to the mid-2005 launch of its CFplus cystic fibrosis test by Genzyme and adoption of its expanded menu selections, primarily the Tag-It Ashkenazi Jewish Panel and the Tag-It CF70 reagents.

 

R&D spending remained flat year over year at $1 million.

 

Tm's first-quarter net loss rose to $4.1 million, or $.09 per share, from a year-ago loss of $3.4 million, or $.09 per share.

 

As of March 31, the company had cash, cash equivalents, and short-term investments totaling $7.5 million.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.